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Background: To evaluate the prognostic significance of the pre-operative C-reactive protein (CRP) serum level in
patients with renal cell cancer (RCC).
Methods: We evaluated 1,161 RCC patients with complete patient and tumour specific characteristics as well as
information about their pre-operative CRP-level, who had undergone either radical nephrectomy or nephron-
sparing surgery at two German high-volume centres (University Hospitals of Hannover and Ulm). The mean follow-
up was 54 months.
Results: The CRP-level, stratified to three subgroups (CRP≤ 4, 4–10, and >10 mg/l), correlated significantly with
tumour stage (p < 0.001), the risk of presenting nodal disease (2.1, 3.1, and 16.4%) and distant metastasis (2.9, 8.6,
and 30.0%; p < 0.001). The Kaplan-Meier 5-year cancer specific survival (CSS) rates were 89.4, 77.9, and 49.5%,
respectively (p < 0.001). Multivariate analysis identified CRP as an independent prognosticator for CSS as well as
overall survival (p < 0.001). Patients with a CRP of 4–10 and >10 mg/l had a 1.67 and 2.48 fold higher risk of dying
due to their RCC compared to those with a pre-operative CRP ≤4 mg/l, respectively.
Conclusions: A high preoperative serum CRP level is an independent predictor of poor survival in patients with
RCC. Its routine use could allow better risk stratification and risk-adjusted follow-up of RCC patients.
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More than 40,000 new cases of renal cell carcinoma
(RCC) are diagnosed in the European Union every year
and about half of these patients will eventually die from
RCC [1]. Despite increased health care facilities for im-
aging and consequent early diagnosis, still up to one
third of all patients with RCC will have metastases at
time of presentation [2]. Of the remaining two thirds,
approximately 20–40% of those treated with (partial)
nephrectomy in case of localized disease, do eventually
develop metachronous metastasis or locally recurring
cancer [3-5]. As patients’ clinical courses vary and are
difficult to predict, the stratifications of patients to ap-
propriate postoperative surveillance programs and differ-
ent therapeutic strategies tailored to the risk of cancer* Correspondence: steffens.sandra@mh-hannover.de; astrid-Koehler@web.de
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reproduction in any medium, provided the orprogression will become increasingly important. There-
fore, the area of defining new prognostic markers is of
active interest [6,7], especially biomarkers in body fluids
offer the opportunity for more objective and reprodu-
cible measurement prior to RCC surgery.
C-reactive protein (CRP) is an acute phase protein
produced almost exclusively by the liver. CRP plasma
levels can increase up to 1000-fold in response to micro-
bial infection, trauma, infarction, autoimmune, or malig-
nant diseases [8-11].
Elevated CRP levels can be a result of an underlying
cancer and a premalignant state, respectively, as well as
due to tumour growth associated tissue inflammation.
However, it is still unclear if the tumor promotes inflam-
mation or if inflammation promotes tumor aggressive-
ness. Experimental studies showed that at least some
renal tumours produce interleukin-6, which promotes
growth of RCC and therefore the presence of systemicl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ness [12,13].
A study published in 2009 by Allin et al. involving
10,408 individuals showed that elevated CRP is associated
with increased risk of cancer, e.g. lung or colorectal malig-
nancies [14]. Furthermore, an elevated CRP level was asso-
ciated with an early death, even in patients without
metastases [14]. Trichopoulos et al. [15] revealed that ele-
vated CRP can be related to a higher risk of developing
bladder cancer. Moreover, in patients with advanced blad-
der cancer undergoing chemotherapy elevated CRP levels
were shown to be associated with a poor clinical outcome
[16]. In addition, also in patients undergoing surgery for
upper-tract urothelial carcinoma an increased CRP level
seems to predict a poor survival [17]. Furthermore, other
recent studies indicated that CRP, next to prostate specific
antigen (PSA), could serve as an additional independent
prognostic marker for tumor-specific survival in meta-
static castration-resistant prostate cancer [18].
Smaller studies published in recent years which
included from 40 up to 313 patients indicated that the
preoperative CRP level could also be associated with
RCC-specific mortality [19-26]. These smaller trials have
shown a potential relationship between circulating CRP
levels and tumour stage as well as a significant impact
on the prognosis of patients with RCC.
In this large study including 1,116 patients, we have
comprehensively analysed the potential pre-operative
prognostic significance of CRP in patients with all
stages and histological subtypes of RCC undergoing
RCC-surgery.
Patients and methods
Patients and tumour characteristics
This study included 1,161 patients with complete patient
and tumour specific characteristics as well as informa-
tion about their pre-operative CRP-level, who underwent
renal tumour surgery 1990–2010 for RCC at the
Hannover (1995–2006) or Ulm (1995–2010) University
Medical Centres. The histological tumour subtype was
determined according to the 1997 UICC Classification.
Staging was based on the 2002 TNM Classification. In-
formation on patients’ and tumour characteristics, such
as age, sex, stage, presence of regional lymph node or
distant metastases, histological subtype, Fuhrman grade,
and CRP-value, was obtained from our computerized in-
stitutional databases.
The pre-operative CRP-value was categorized accord-
ing to Johnson et al. [27], i.e. low level: CRP ≤ 4 mg/l,
intermediate: 4–10 mg/l, and high: >10 mg/l.
Follow up
The duration of the follow-up was calculated from date
of surgery to the date of death or last follow-up. Deathwas assessed as either cancer-related or -unrelated. The
primary end point of this study was cancer-specific sur-
vival (CSS). Information about the exact date as well as
cause of death for each patient was received from the
patient’s general practitioner, a close family member or
the patient’s hospital records if she/he had been fol-
lowed up or died in one of our institutions. Follow-up
assessment ended in October 2011. Until then, all
patients’ data were updated at least every 6 months on
a regular basis.
Statistical methods
Continuous variables were reported as mean value and
standard deviation (SD) or median value and interquar-
tile ranges (IQR) in the case of parametric or non-
parametric distribution, respectively. Chi2 tests were
conducted to assess correlations of covariate distribu-
tions and CRP-groups.
Receiver operation characteristics (ROC) curves were
constructed to assess the potential of preoperative CRP
to predict overall and cancer-specific survival and to
identify cut-offs to categorise CRP-levels in risk groups.
Kaplan-Meier estimates of survival time were calcu-
lated, and subgroups were compared by the log rank test
statistic. Multivariate Cox regression models were used
to assess the association between survival and CRP-
levels adjusted for different clinical and patient covari-
ates (i.e., age, sex, tumour stage and grade, the histo-
logical subtype, and metastatic status). SPSS 19.0 was
used for statistical assessment. In all tests, a two-sided
p < 0.05 was considered to indicate significance.
Results
Our patient population of 761 (65.6%) men and 400
(34.4%) women had a mean age of 61.9 years (19–90).
989 (87.1%), 86 (7.6%), 26 (2.3%), and 34 (3.0%) of all
patients suffered from clear cell, papillary, chromophobe,
and non-classified RCC, respectively. The median body
mass index (BMI) for all patients was 26.5 kg/m2 (IQR,
24.0 – 29.4). 880 (75.9%) and 281 (24.1%) were treated
with radical and partial nephrectomy. Detailed patients’
and tumour characteristics including stage and grade are
summarized in Table 1.
The median/mean follow-up was 46/54 months (IQR,
19 – 84). By the last day of data acquisition, 279 (24.0%)
had died from their tumour disease and 48 (4.1%) from
other causes.
Clinical parameters
Mean (median) pre-operative CRP value was 21.6 (4.0)
mg/l. The mean (median) CRP value in the three sub-
groups (CRP ≤ 4, 4–10, and >10 mg/l) was 2.5 (2.6), 6.9
(6.8), and 58.6 (38.0) mg/l, respectively. The three
groups were comparable concerning the distribution of
Table 1 Association between different patient and cancer-specific variables with the pre-operative CRP value
Variable CRP <4 mg/l CRP 4–10 mg/l CRP >10 mg/l p-value Test
Age, mean (95% CI) 60.9 (59.9 - 61.9) 62.1 (60.4 - 63.8) 63.4 (62.4 - 64.5) 0.005 ANOVA
Sex 0.28 chi-square
female 225 (36.5%) 51 (31.3%) 124 (32.5%)
male 391 (63.5%) 112 (68.7%) 258 (67.5)
Side 0.81 chi-square
right 325 (52.8%) 86 (52.8%) 193 (50.5%)
left 286 (46.5%) 77 (47.2%) 187 (49.0%)
bilateral 4 (0.7%) 0 2 (0.5%)
Type of surgery <0.001 chi-square
Radical nephrectomy 408 (66.2%) 130 (79.8%) 342 (89.8%)
Partial nephrectomy 208 (33.8%) 33 (20.2%) 39 (10.2%)
Stage <0.001 chi-square
pT1a 284 (46.6%) 58 (35.8%) 39 (10.4%)
pT1b 164 (26.9%) 40 (24.7%) 55 (14.7%)
pT2 44 (7.2%) 15 (9.3%) 44 (11.7%)
pT3a 66 (10.8%) 23 (14.2%) 78 (20.8%)
pT3b/c 49 (8.2%) 26 (16.0%) 142 (37.9%)
pT4 2 (0.3%) 0 17 (4.5%)
LN metastasis1 13 (2.1%) 5 (3.1%) 62 (16.4%) <0.001 chi-square
Pulmonal/visceral metastasis1 18 (2.9%) 14 (8.6%) 114 (30.0%) <0.001 chi-square
Grade <0.001 chi-square
G1 144 (23.8%) 30 (18.9%) 26 (7.0%)
G2 416 (68.8%) 110 (69.2%) 212 (56.7%)
G3 45 (7.4%) 18 (11.3%) 127 (34.0%)
G4 0 1 (0.6%) 9 (2.4%)
Histological subtype 0.08 chi-square
non ccRCC 86 (14.3%) 24 (14.9%) 36 (9.7%)
ccRCC 516 (85.7%) 137 (85.1%) 336 (90.2%)
1at time of renal surgery. Abbreviations: CRP = C reactive protein, RCC = renal cell carcinoma, ccRCC = clear-cell RCC, LN = lymph node.
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with a higher CRP level were significantly older (mean,
60.9 vs. 62.1 vs. 63.4 years; p = 0.005; ANOVA). More-
over, patients with a BMI <25 had significantly more
often high CRP values than those with a BMI >30 kg/m2
(35.8 vs. 24.7%; p < 0.001; Chi2 test).
Tumour-specific parameters
The CRP-level correlated significantly with the tumour
stage: 19.3, 30.2, and 63.2% of all patients with a CRP ≤4,
4–10, and >10 mg/l suffered from locally advanced (pT≥
3, Nany, Many) RCC at the time diagnosis (p < 0.001, Chi
2
test). The risk of presenting nodal disease (2.1, 3.1, and
16.4%) or distant metastasis (2.9, 8.6, and 30.0%) also
increased significantly in each CRP-group (p< 0.001, Chi2
test; Table 1). Accordingly, the median CRP value was sig-
nificantly higher in advanced (pT3-4 and/or N/M+) thanin localized (pT1-2, N/M-) disease (16.0 vs. 4.0 mg/l;
p < 0.001, Mann–Whitney-test).
Moreover, high (>10 mg/dl) CRP-levels were found in
13.0, 28.7, 66.8, and 90.0% of patients with G1, G2, G3,
and G4 differentiated RCC (p < 0.001, Chi2 test).
Clinical course and oncological outcome
After a mean follow-up of more than 4 years, the
tumour-associated death rates were 12.4, 24.8, and
50.7% in the CRP ≤4, 4–10, and >10 mg/l groups
(p < 0.001, Chi2 test). In accordance, the Kaplan-Meier 5-
year CSS rates were 89.4, 77.9, and 49.5%, respectively
(p < 0.001, log rank; figure 1a). The Kaplan-Meier 5-year
overall survival rates were calculated at 85.5, 71.1, and
46.3%, respectively (p < 0.001, log rank; figure 1b).
Applying receiver-operating characteristic analyses, the
CRP value exhibited an AUC (95% CI) of 0.78 (0.75 –
Figure 1 a) Cancer-specific survival (Kaplan-Meier) for all RCC
patients plotted against the pre-operative CRP-group. The
5-year survival rate was 89.4%, 77.9%, and 49.5% for all evaluable
patients (n = 1,047) with a CRP of ≤4 mg/l (n = 558), 4–10 mg/l
(n = 141), and >10 mg/l (n = 348), respectively (p < 0.001, log rank). b)
Overall survival (Kaplan-Meier) for all RCC patients plotted against
the pre-operative CRP-group. The 5-year survival rate was 85.5%,
71.1%, and 46.3% for all evaluable patients (n = 1,133) with a CRP of
≤4 mg/l (n = 603), 4–10 mg/l (n = 158), and >10 mg/l (n = 372),
respectively (p < 0.001, log rank).
Figure 2 a) Cancer-specific survival (Kaplan-Meier) for organ-
confined RCC plotted against the pre-operative CRP-group: The
5-year survival rate was 93.2%, 86.9%, and 77.0% for all evaluable
patients (n = 634) with a CRP of ≤4 mg/l (n = 437),
4–10 mg/l (n = 93), and >10 mg/l (n = 104), respectively (p < 0.001,
log rank). b) Cancer-specific survival (Kaplan-Meier) for advanced
RCC plotted against the pre-operative CRP-group: The 5-year survival
rate was 76.3%, 58.0%, and 35.9% for all evaluable patients (n = 399)
with a CRP of ≤4 mg/l (n = 114), 4–10 mg/l (n = 47), and >10 mg/l
(n = 238), respectively (p < 0.001, log rank).
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p < 0.001) for overall survival. Moreover, the cut-off
values 4.0 and 10.0 mg/l, as suggested earlier in a smal-
ler trial [27] could be confirmed as highly discriminating
concerning risk classification.
Subgroup analyses comparing localized (pT1-2, N/M0)
and advanced disease (pT3-4 and/or N/M+) confirmed
significant differences in CSS for all three CRP-groups in
both clinical settings (figures 2a + b). The Kaplan-Meier
5-year CSS rates were 93.2, 86.9, and 77.0% for localized(p < 0.001; log rank) and 76.3, 58.0, and 35.9% for
advanced RCC, respectively (p < 0.001; log rank).
Multivariate analysis including age, sex, histological
subtype, tumour stage, and differentiation identified the
CRP-value as a continuous metric variable as an inde-
pendent prognosticator for cancer-specific (HR 1.007,
95% CI: 1.004-1.009; p < 0.001, Cox regression) as well
as overall survival (HR 1.006, 95% CI: 1.004-1.008;
p < 0.001, Cox regression) in patients with RCC. After
its stratification into the three groups (CRP ≤4, 4–10,
and >10 mg/l) the discriminative power and prognostic
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dent. Patients with a CRP of 4–10 and >10 mg/l had a
1.67 and 2.48 fold higher risk of dying due to their RCC
compared to those with a pre-operative CRP ≤4 mg/l,
respectively (Table 2).
Discussion and conclusions
In this large study we could reveal that different CRP
leves were significantly associated with tumour stage,
grade, and a poor cancer specific and overall survival in
patients undergoing resection for RCC. These results
confirmed the association of circulating CRP levels with
the tumour stage and its impact on the prognosis ofTable 2 Multivariable analysis revealed that the pre-
operative CRP-level is an independent prognostic marker
for cancer- specific survival
Variable P value HR (95%CI)






pT1b 0.74 1.08 (0.69-1.69)
pT2 0.34 1.30 (0.76-2.22)
pT3a 0.006 1.90 (1.20-2.99)
pT3b 0.20 1.35 (0.86-2.13)
pT3c 0.35 2.00 (0.46-8.59)
pT4 0.89 0.94 (0.42-2.20)
LN metastases 2 <0.001
N- 1
N+ 3.59 (2.46-5.25)





G2 0.01 1.97 (1.16-3.34)
G3 0.003 2.47 (1.36-4.51)






4-10 mg/l 0.03 1.66 (1.06-2.59)
>10 mg/l <0.001 2.58 (1.83-3.64)
1continuous metric variable, 2 at the time of surgery.patients with RCC. Previous smaller studies which had
included up to 313 patients [24], only, already indicated
that CRP might be an independent predictor of cancer
specific survival in patients with RCC.
Only recently, Johnson et al. [27] presented a study
suggesting a CRP-based prognostic classification of
patients with localized RCC. The authors recommended
to stratify patients according to the CRP cut-off values
4.0 and 10.0 mg/l. We were able to confirm these cut-off
values as highly discriminating concerning both overall
and also cancer specific survival. Furthermore, with our
larger patient cohort, compared to the study by Johnson
et al. [27] (n = 1,161 vs. n = 173), we were able to prove
the impact of the CRP-level as an independent prognos-
tic predictor for both patients with localized and
advanced disease.
Lamb et al. [25] indicated that the presence of a pre-
operative systemic inflammatory response measured in
an elevated CRP level might be an independent nega-
tive predictor for relapse-free survival in patients with
localized RCC after curative surgery. However, Lamb
and co-workers evaluated 60 patients with localized
clear cell RCC, only, and used a CRP level of >10 mg/l
as cut off point.
An elevated circulating CRP concentration had also
been suggested to be a poor prognostic factor in
patients with metastatic RCC [10,12,28]. Masuda et al.
[29] published a retrospective study including patients
with advanced RCC which identified the CRP-level as a
prognostic factor independent of tumour stage and
grade. However, the threshold for CRP was not defined
in their survival analysis. In contrast, Ito et al. [22] were
able to demonstrate in a cohort of 178 patients that a
CRP elevation >10 mg/l might be an independent pre-
dictor for recurrence and prognosis in both localized
and metastatic RCC. Interestingly, the mean CRP levels
in the study by Ito et al. [22] and our own study were
similar, i.e. 21 mg/l and 21.6 mg/l, respectively.
Lamb et al. [25] showed that the tumour cell expres-
sion of IL-6 was not significantly associated with circu-
lating CRP levels hypothesizing that the main source of
IL-6 causing an elevated CRP level is not the tumour it-
self. In contrast, in 2005 Jabs et al. [25] published a study
with 40 patients suggesting that the CRP expression by
the tumour itself is directly associated with the circulat-
ing CRP concentration indicating an autonomous pro-
duction of CRP in the tumor and normal kidney tissue.
Accordingly, Johnson et al. [30] only recently evaluated
the influence of intratumoral CRP on overall survival in 95
patients with localized clear cell RCC using immunohisto-
chemical analysis. The tumours were categorized into low,
intermediate, and high CRP staining intensity. Mean overall
survival was significantly longer in the low (44.2 months)
and intermediate (40.5 months) risk (i.e. CRP) group
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amounts of CRP (31.6 months; p= 0.002 and p=0.067).
Applying multivariate analysis, patients with high intratu-
moural CRP levels experienced a 12-fold increased risk of
overall mortality compared to patients with low CRP
expressing tumours.
As biomarkers in fluids offer the opportunity for more
objective and reproducible measurement prior to
tumour surgery, the use of CRP as a well-standardized
parameter worldwide, should not be underestimated. Ra-
ther than tumour tissue-based factors, it can easily be
implemented as a prognostic factor in addition to
tumour stage and grade, to more accurately stratify
patients with RCC. Karakiewicz et al. [24] were able to
show in a group of 313 patients that the incorporation
of the CRP value into the UISS scoring systems for
patients with localized RCC might improve its prognos-
tic significance. Furthermore, Iimura et al. introduced
the TNM-C Score, a prediction model including C-
reactive protein in patients treated with nephrectomy for
clear cell RCC [19]. In a cohort of 249 patients - and
290 for external validation - they were able to show that
the model is a useful tool to predict cancer specific sur-
vival [19]. However, to our knowledge, the incorporation
of CRP in a prognostic model is not yet an established
tool used in clinical routine.
In conclusion, this large study confirms that the pre-
operative CRP-level is an independent prognostic factor
in patients with RCC. A high preoperative serum CRP
level is significantly associated with poor survival in
patients with both localized and advanced RCC. Its rou-
tine use could allow better risk stratification and risk-
adjusted follow-up for patients with kidney cancer.
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